Philippe Paparel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philippe Paparel has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Alain Ruffion
Service D’urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69002 Lyon, France
3 shared publications A-R. Azzouzi
2 shared publications- Alain Ruffion
Urology Department, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon Cancer Innovation Center (EA 3738 CICLY), Lyon Sud Medical School, University of Lyon 1, Lyon, France
2 shared publications - Bernard Escudier
Institut Gustave Roussy, Villejuif
2 shared publications D. Champetier
2 shared publicationsE. Xylinas
2 shared publications
Latest Publications
- 1 September 2017
- Published by Elsevier in Médecine Nucléaire
- Vol. 41 (5) , 329-334
Epidémiologie, diagnostic et pronostic du cancer de la prostate
- 1 September 2017
- Published by Elsevier in Médecine Nucléaire
- Vol. 41 (5) , 329-334
Epidémiologie, diagnostic et pronostic du cancer de la prostate
- 1 March 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (1) , e1105
1105 Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy. A French retrospective study of 13 cases
- 1 March 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (1) , e1105
1105 Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy. A French retrospective study of 13 cases
- 1 March 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (1) , e87-e88
87 Morbidity, functional and oncological outcomes after nephron sparing surgery for cT2 renal tumours
- 1 March 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (1) , e87-e88
87 Morbidity, functional and oncological outcomes after nephron sparing surgery for cT2 renal tumours
- 29 February 2012
- Published by Elsevier in European Urology Supplements
- Vol. 11 (1) , e640-e640a
640 Millin suprapubic adenomectomy obsolete or still gold standard in the era of laparoscopic or laser enucleation for BPH? Results of a series of 240 consecutive cases and a post-operative hospital stay of 4.6 days
- 29 February 2012
- Published by Elsevier in European Urology Supplements
- Vol. 11 (1) , e640-e640a
640 Millin suprapubic adenomectomy obsolete or still gold standard in the era of laparoscopic or laser enucleation for BPH? Results of a series of 240 consecutive cases and a post-operative hospital stay of 4.6 days
- 1 September 2007
- Vol. 24 (2) , 95-101
Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall.
Sarcoidosis is a multisystemic, non-caseous, benign granulomatous disease of unknown etiology that is sometimes associated with testicular cancer. This association, which does not appear to be accidental, can give rise to diagnostic problems because adenopathies or parenchymatous pulmonary nodules related to sarcoidosis can lead to the presumption of metastatic testicular cancer. The objective of this article was to assess the clinical, histological, and radiological characteristics of the association between sarcoidosis and testicular cancer to help clinicians avoid potentially fatal diagnostic traps and management errors. Literature review. A total of 64 cases of sarcoidosis concomitant with testicular cancer were described in the literature. In more than 50% of the cases (35/64), testicular cancer was diagnosed before sarcoidosis or sarcoid-like reaction. Cancer was diagnosed concomitantly in 31% of cases (20/64). Every anatomopathological type of testicular tumor was described in association with sarcoidosis. Seminoma was the most frequent tumor, occuring in 62% (40/64) of patients. In 80% of the cases (51/64) sarcoidosis regressed spontaneously. Testis cancer may be accompanied by a sarcoid-like reaction or can be associated with real sarcoidosis. The association of testicular cancer with sarcoidosis did not change the therapeutic management of either of these two pathologies. The presence of sarcoidosis does not change the cancer prognosis. Sarcoidosis is a benign disease that resolved favorably and spontaneously in 80% of the cases.
- 1 September 2007
- Vol. 24 (2) , 95-101
Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall.
Sarcoidosis is a multisystemic, non-caseous, benign granulomatous disease of unknown etiology that is sometimes associated with testicular cancer. This association, which does not appear to be accidental, can give rise to diagnostic problems because adenopathies or parenchymatous pulmonary nodules related to sarcoidosis can lead to the presumption of metastatic testicular cancer. The objective of this article was to assess the clinical, histological, and radiological characteristics of the association between sarcoidosis and testicular cancer to help clinicians avoid potentially fatal diagnostic traps and management errors. Literature review. A total of 64 cases of sarcoidosis concomitant with testicular cancer were described in the literature. In more than 50% of the cases (35/64), testicular cancer was diagnosed before sarcoidosis or sarcoid-like reaction. Cancer was diagnosed concomitantly in 31% of cases (20/64). Every anatomopathological type of testicular tumor was described in association with sarcoidosis. Seminoma was the most frequent tumor, occuring in 62% (40/64) of patients. In 80% of the cases (51/64) sarcoidosis regressed spontaneously. Testis cancer may be accompanied by a sarcoid-like reaction or can be associated with real sarcoidosis. The association of testicular cancer with sarcoidosis did not change the therapeutic management of either of these two pathologies. The presence of sarcoidosis does not change the cancer prognosis. Sarcoidosis is a benign disease that resolved favorably and spontaneously in 80% of the cases.
- 21 August 2007
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 11 (2) , 181-186
Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study
The objective of this study was to evaluate mechanisms of the synergy between high intensity-focused ultrasound (HIFU) and docetaxel and to determine the best sequence of chemotherapy administration in relation to HIFU treatment for obtaining optimum control of tumoral growth. A total of 15 days after s.c. implantation of the tumor, 52 Copenhagen rats studied were randomized in 4 groups of 13: controls, docetaxel alone (group 1), HIFU and docetaxel concomitant (group 2) and HIFU and docetaxel administered 24 h before treatment (group 3). The number of HIFU shots was calculated in order to cover 75% of the tumor volume. The effects of docetaxel, HIFU and their interaction on tumor volumes were analyzed using a linear regression. The distributions of the tumor volumes were significantly greater in the control group than in the group 1 (P=0.002) and than in both groups 2 and 3 (PP=0.0001). These volumes were also significantly greater in group 1 than in both groups 2 and 3 and there was no difference between the groups 2 and 3. The tumor doubling times were 7.8 days for the group 1, 43.8 days for the group 2, 16.1 days for the group 3 and 5.9 days for the controls. The mechanism of the synergy between HIFU and docetaxel on the growth of Dunning tumors is apparently multifaceted. The results are encouraging because in the two groups of rats treated with the combination of HIFU and docetaxel, the percentage of complete remission was approximately 30%.
- 21 August 2007
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 11 (2) , 181-186
Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study
The objective of this study was to evaluate mechanisms of the synergy between high intensity-focused ultrasound (HIFU) and docetaxel and to determine the best sequence of chemotherapy administration in relation to HIFU treatment for obtaining optimum control of tumoral growth. A total of 15 days after s.c. implantation of the tumor, 52 Copenhagen rats studied were randomized in 4 groups of 13: controls, docetaxel alone (group 1), HIFU and docetaxel concomitant (group 2) and HIFU and docetaxel administered 24 h before treatment (group 3). The number of HIFU shots was calculated in order to cover 75% of the tumor volume. The effects of docetaxel, HIFU and their interaction on tumor volumes were analyzed using a linear regression. The distributions of the tumor volumes were significantly greater in the control group than in the group 1 (P=0.002) and than in both groups 2 and 3 (PP=0.0001). These volumes were also significantly greater in group 1 than in both groups 2 and 3 and there was no difference between the groups 2 and 3. The tumor doubling times were 7.8 days for the group 1, 43.8 days for the group 2, 16.1 days for the group 3 and 5.9 days for the controls. The mechanism of the synergy between HIFU and docetaxel on the growth of Dunning tumors is apparently multifaceted. The results are encouraging because in the two groups of rats treated with the combination of HIFU and docetaxel, the percentage of complete remission was approximately 30%.
- Open Access
- 8 April 2007
- Published by Wiley in BJU International
- Vol. 99 (5) , 1191-1196
Surgical principles of omentoplasty in urology
- 8 April 2007
- Published by Wiley in BJU International
- Vol. 99 (5) , 1191-1196
Open AccessSurgical principles of omentoplasty in urology
- 17 January 2006
- Published by Wiley in BJU International
- Vol. 97 (2) , 338-341
The epidemiology of trauma of the genitourinary system after traffic accidents: analysis of a register of over 43 000 victims
OBJECTIVE: To analyse the frequency and type of injury to the genitourinary system, by user category, after traffic accidents. PATIENTS AND METHODS: The register which forms the basis of this study is unique in Europe and includes 43 056 victims of road traffic accidents, and was compiled between 1996 and 2001. The categories of road users included: motorists, motorcyclists, cyclists, pedestrians, van and bus users, and roller skaters. The urological complication rate was analysed for each category. RESULTS: In all, 199 cases of trauma of the genitourinary system (0.46%) were recorded. The most frequent urological complications were renal (43%) and testicular trauma (24%), the former most frequent in motorists (65%) and pedestrians (29%), and the latter in motorcyclists (41%). CONCLUSIONS: An analysis of this register provides better knowledge of the urogenital injuries after traffic accidents. Renal and testicular injuries are the most frequent.
- 17 January 2006
- Published by Wiley in BJU International
- Vol. 97 (2) , 338-341
The epidemiology of trauma of the genitourinary system after traffic accidents: analysis of a register of over 43 000 victims
OBJECTIVE: To analyse the frequency and type of injury to the genitourinary system, by user category, after traffic accidents. PATIENTS AND METHODS: The register which forms the basis of this study is unique in Europe and includes 43 056 victims of road traffic accidents, and was compiled between 1996 and 2001. The categories of road users included: motorists, motorcyclists, cyclists, pedestrians, van and bus users, and roller skaters. The urological complication rate was analysed for each category. RESULTS: In all, 199 cases of trauma of the genitourinary system (0.46%) were recorded. The most frequent urological complications were renal (43%) and testicular trauma (24%), the former most frequent in motorists (65%) and pedestrians (29%), and the latter in motorcyclists (41%). CONCLUSIONS: An analysis of this register provides better knowledge of the urogenital injuries after traffic accidents. Renal and testicular injuries are the most frequent.
- 24 March 2005
- Published by Wiley in BJU International
- Vol. 95 (6) , 881-885
Synergistic inhibitory effect of high‐intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma
OBJECTIVE: To evaluate the therapeutic effect of high‐intensity focused ultrasound (HIFU) combined with chemotherapy (paclitaxel + estramustine) on AT2 Dunning adenocarcinoma, as no satisfactory treatment for localized prostate cancer is available for patients with a poor prognosis, e.g. stage T3, a high Gleason score, or a prostate‐specific antigen level of >15 ng/mL. MATERIALS AND METHODS: Forty‐one Dunning AT2 tumour‐bearing Copenhagen rats were divided into four groups, i.e. control, chemotherapy, HIFU, and chemotherapy + HIFU (the last three treated for 1 week). The growth in tumour volume was recorded for 3 weeks, the point at which tumour volume was considered to have doubled (doubling time). The growth curves of each group were plotted and evaluated statistically. RESULTS: At 30 days of follow‐up the distributions of tumour volume with treatment group were significantly different ( P < 0.001); volumes were significantly greater in the control than in the chemotherapy‐only or in the HIFU‐only group (both P = 0.006). The greatest difference was between the chemotherapy + HIFU and the control group. The tumour doubling times were 13.2 days for HIFU‐only, 31.2 days for chemotherapy + HIFU and 7.7 days for the controls. CONCLUSION: These results suggest that this combined therapy could be useful for treating patients with high‐risk prostate cancer.
- 24 March 2005
- Published by Wiley in BJU International
- Vol. 95 (6) , 881-885
Synergistic inhibitory effect of high‐intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma
OBJECTIVE: To evaluate the therapeutic effect of high‐intensity focused ultrasound (HIFU) combined with chemotherapy (paclitaxel + estramustine) on AT2 Dunning adenocarcinoma, as no satisfactory treatment for localized prostate cancer is available for patients with a poor prognosis, e.g. stage T3, a high Gleason score, or a prostate‐specific antigen level of >15 ng/mL. MATERIALS AND METHODS: Forty‐one Dunning AT2 tumour‐bearing Copenhagen rats were divided into four groups, i.e. control, chemotherapy, HIFU, and chemotherapy + HIFU (the last three treated for 1 week). The growth in tumour volume was recorded for 3 weeks, the point at which tumour volume was considered to have doubled (doubling time). The growth curves of each group were plotted and evaluated statistically. RESULTS: At 30 days of follow‐up the distributions of tumour volume with treatment group were significantly different ( P < 0.001); volumes were significantly greater in the control than in the chemotherapy‐only or in the HIFU‐only group (both P = 0.006). The greatest difference was between the chemotherapy + HIFU and the control group. The tumour doubling times were 13.2 days for HIFU‐only, 31.2 days for chemotherapy + HIFU and 7.7 days for the controls. CONCLUSION: These results suggest that this combined therapy could be useful for treating patients with high‐risk prostate cancer.